Modified Finnegan Neonatal Abstinence Score (NAS)
Pharmacologic treatment required if
The Modified Finnegan Neonatal Abstinence Score is a symptom‑based tool used to quantify opioid withdrawal severity in newborns to guide treatment decisions.
Indications d'utilisation
Used to assess opioid‑withdrawal severity in term or near‑term infants exposed to prenatal opioids and guide need for pharmacologic therapy. Helps standardize monitoring, track response to treatment, and determine timing/intensity of supportive care. Identifies infants at risk for complications and assists decisions on initiation, escalation, or weaning of therapy.
Informations et précautions
Scores are highly sensitive for detecting infants needing treatment but remain subjective and inconsistently validated; shortened versions correlate well with treatment thresholds yet lack robust psychometrics 1 [Level III evidence]. Observational bias, poor internal consistency, and limited applicability to preterm infants are major cautions 2 [Level III evidence]. ESC‑based care reduces overtreatment and LOS, underscoring that score-driven algorithms may overestimate severity 3 [Level I evidence].